Nuvation Bio initiated with an Outperform at Citizens JMP

Citizens JMP analyst Silvan Tuerkcan initiated coverage of Nuvation Bio (NUVB) with an Outperform rating and $6 price target Nuvation is a clinical-stage biotechnology company focused on developing novel targeted therapies for various cancer types, the analyst tells investors in a research note. The firm says that in the current climate, it favors commercial or near-commercial companies that have potential for rapid sales growth. It views Nuvation’s taletrectinib as the best-in-class potential ROS1 TKI for the treatment of ROS1-positive, non-small cell lung cancer.